http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101983547-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-10 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B40-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5044 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5014 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H50-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H10-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H20-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B40-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
| filingDate | 2017-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101983547-B1 |
| titleOfInvention | Personalized anticancer chemotherapy screening system and process using a short-term culture circulating tumor cell(ctc) |
| abstract | The present invention relates to a screening system capable of performing the method and screening method for individualized anticancer drugs. In the present invention, short-term culture blood cancer cells (CTC) are utilized to acquire genetic information of cancer cells. Blood cancer cells can be obtained by separating blood from blood collected from cancer patients. Therefore, it is less dangerous than the method of examining the anticancer response to conventional cell tissues, and it is also easy to recollect blood in a short period if necessary. Using the personalized anticancer agent screening method utilizing the short-term cultured blood cancer cells of the present invention, a customized anticancer drug can be prescribed according to the genetic trait of an individual rather than uniformly prescribing the same one disease. In addition, it is possible to reduce the risk of side effects associated with chemotherapy, as well as to reduce the cost and time for chemotherapy by pre-selecting a customized anticancer drug rather than a uniform treatment. |
| priorityDate | 2016-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 207.